Company: BNBX
Filing Date: 2025-12-22
Form Type: 10-K
Source: 0001104659-25-123342
Chunk: 5

Company: BNB PLUS CORP.
Filing Date: 2025-12-22
Form: 10-K
Item: Item 11E
Chunk 5
---
ITEM 11.EXECUTIVE COMPENSATION

Compensation Overview

The Compensation Committee has overall responsibility for approving and evaluating the compensation arrangements for our named executive officers. Our named executive officers for fiscal 2025 are:

●Dr. James Hayward, who served as our Chairman and Chief Executive Officer through June 18, 2025;

●Judith Murrah, who served as our President, Chief Operating Officer and our Chief Information Officer through June 18, 2025 and then our Chairperson and Chief Executive Officer from June 18, 2025 through September 29, 2025;

●Clay Shorrock, our Chief Legal Officer, Executive Director of Business Development and President of LineaRx, and then our Chief Executive Officer and President from September 29, 2025; and

●Beth Jantzen, our Chief Financial Officer.

Our Chief Executive Officer may provide recommendations to the Compensation Committee with respect to the compensation of the named executive officers other than for the Chief Executive Officer. However, the Compensation Committee is free to make decisions that are contrary to the Chief Executive Officer’s recommendations.

On June 18, 2025, Dr. Hayward resigned as the Chairman and CEO and Judith Murrah was appointed Chairperson and CEO of the Company. On September 29, 2025, Ms. Murrah resigned as CEO and President of the Company and Clay Shorrock was appointed CEO and President of the Company.